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ABSTRACT
Background: Atrial fibrosis can promote atrial fibrillation (AF). Electroanatomic 
mapping (EAM) can provide information regarding local voltage abnormalities that 
may be used as a surrogate marker for fibrosis. Specific voltage cut-off values have 
been reproduced accurately to identify fibrosis in the ventricles, but these values are 
not well defined in atrial tissue.
Methods: This study is a prospective single-center study. Patients with persistent AF 
referred for ablation were included. EAM was performed before ablation. We 
recorded bipolar signals, first in AF and later in sinus rhythm (SR). Two thresholds 
delimited low-voltage areas (LVA), 0.5 and 0.3 mV. We compared LVA extension 
between maps in SR and AF in each patient.
Results: A total of 23 patients were included in the study. The percentage of points 
with voltage lower than 0.5 mV and 0.3 mV was significantly higher in maps in AF 
compared with maps in SR: 38.2% of points < 0.5 mV in AF vs. 22.9% in SR (p < 
0.001); 22.3% of points < 0.3 mV in AF vs. 14% in SR (p < 0.001). Areas with 
reduced voltage were significantly larger in maps in AF (0.5 mV threshold, mean area
in AF 41.3 ± 42.5 cm2 vs. 11.7 ± 17.9 cm2 in SR, p < 0.001; 0.3 mV threshold, mean 
area in AF 15.6 ± 22.1 cm2 vs. 6.2 ± 11.5 cm2 in SR, p < 0.001).
Conclusions: Using the same voltage thresholds, LVA extension in AF is greater than 
in SR in patients with persistent AF. These findings provide arguments for defining a 
different atrial fibrosis threshold based on EAM rhythm.
Key words: atrial fibrillation, electroanatomic mapping, low-voltage areas, atrial
fibrosis threshold, pulmonary vein isolation
INTRODUCTION
Atrial fibrillation (AF) is the most common cardiac tachyarrhythmia. The 
pathophysiology of AF is complex [1] and can be described as follows [2]: 1) triggers 
for the initiation of arrhythmia (pulmonary and nonpulmonary foci); 2) a fibrotic 
substrate for the maintenance of AF; and 3) various modulators acting by multiple 
potential mechanisms (such as hypertension, obesity, obstructive sleep apnoea, 
inflammation, and endurance sports).
Atrial remodelling and fibrosis development are associated with a variety of 
electric disturbances, such as heterogeneities in atrial action potential duration, 
effective refractory period, and conduction velocity [3]. These phenomena can 
promote and sustain AF.
Left atrial (LA) scarring can be detected by late enhancement magnetic resonance
(MRI-DE) and can be correlated well with reduced electrogram amplitudes as 
recorded by endocardial voltage maps [4]. However, MRI to assess atrial fibrosis is 
not available in all centers because of its complex evaluation. Electroanatomic 
mapping (EAM) can provide information regarding local voltage abnormalities that 
may be used as a surrogate marker for fibrosis. Specific voltage cut-off values have 
been reproducibly shown accurately to identify scars and/or fibrosis in the ventricles 
[5, 6]. EAM voltage cut-off values to identify myocardial scars in the atrial tissue are 
not as well defined as in the ventricle. Voltage-guided AF substrate modification 
targeting low voltage areas (LVAs) has been carried out in some studies to improve 
long-term AF ablation efficacy [7–12]. In most of them, mapping was performed 
using voltage cut-offs during sinus rhythm (SR), and in one study, mapping was 
performed during AF [12]. However, a recent study documented that the correlation 
between low-voltage and posterior LA MRI-DE is significantly improved when 
acquired during AF vs. SR [13]. All of these studies used a cut-off point of 0.5 mV to 
define low voltage, although some of them also used other cut-off points such as 0.1 
or 0.2 mV to define the scar area. Some of them used a 3.5 mm saline-irrigated 
catheter for mapping [8, 9], Jadidi et al. [10] used a 20-pole mapping catheter whereas
others studies combined two types of catheters, a decapolar or a 20-pole mapping 
catheter and a 3.5 mm saline-irrigated catheter [7, 11].
The aim of the present study was to evaluate the LVA extent and location in 
patients with persistent AF undergoing pulmonary vein isolation (PVI) and to 
compare the findings on maps obtained in SR and AF in each patient. 
METHODS
This study was a prospective single-center study. Patient demographics, clinical 
characteristics, and medications were exported from patient records. All participants 
provided written informed consent for the ablation procedure and for inclusion in 
medical research at the time of the procedure.
Study population
All consecutive patients with persistent AF referred to the documented center for 
PVI were included (between September 2016 and June 2019). Exclusion criteria were 
redo ablations (to avoid bias owing to prior ablations, which could affect AF 
substrate) and patients who arrived in SR on the procedure day.
Electroanatomic mapping and ablation
All procedures were performed under general anaesthesia. Antiarrhythmic agents,
if present, were not discontinued. Patients maintained anticoagulant treatment 
(acenocumarol with an international normalized ratio from 2 to 3.5, or direct oral 
anticoagulants, with the last dose the night before the procedure).
After vascular access was obtained, a double transseptal puncture was performed,
and intravenous heparin was administered to maintain an activated clotting time of 
more than 300 s. Thereafter, two long sheaths (1 SL0 sheath and 1 Agilis sheath; St. 
Jude Medical, Inc., St. Paul, MN) were inserted into the LA. The following catheters 
were used: a decapolar catheter WEBSTER® CS Catheter (Biosense Webster) was 
placed in the coronary sinus as a reference (6Fr), a Pentaray® catheter (Biosense 
Webster) with F curve 2-6-2 mm spacing between electrodes (7Fr) as a high-density 
mapping catheter (10 pairs of electrodes) and a SmartTouch SF with an F curve as an 
irrigated-tip contact force ablation catheter (7.5Fr).
The three-dimensional geometry of the LA and 4 pulmonary veins (PVs) was 
reconstructed with the use of the Carto3 mapping system version 6 (Biosense Webster,
Inc.). To ensure that the mapping catheter was in contact with the tissue, the CARTO 
system features the TPI or tissue proximity indicator, which performs an impedance 
matrix. When it contacts the cardiac wall, the catheter has less ion-charged blood, so 
impedance rises. To carry out the automatic acquisition of points, a series of filters 
were included. Multiple bipolar signals (filter setting: 30–300 Hz) were recorded from
the Pentaray catheter, first in AF and later in SR after electrical cardioversion. 
Operators mapped carefully to ensure that the entire LA anatomy was represented in 
both the SR and AF maps. All points within the pulmonary veins and LA appendage 
were excluded. After both electroanatomical maps were completed, ablation was 
performed as usual in our center: ipsilateral PVI in pairs, with entrance and exit block 
as the electrophysiological endpoint. In some cases, ablation could also include lines 
of ablation at the operator’s discretion.
All procedures were performed by two expert operators.
Fibrosis area measurement
Two thresholds, selected according to the literature, were established to delimit 
LVA: 0.5 mV and 0.3 mV. The condition of presenting voltages higher than or equal 
to 0.1 mV was added to avoid areas of dense fibrosis and possible false voltages, 
which might be due to contact problems or which may represent electrical noise.
To delimitate LVA extension, a tool present in CARTO called “area 
measurement”  was used. With this tool, low voltage extension is manually drawn 
according to the color code given by the chosen thresholds. Since this measurement 
process is performed manually, there may be discrepancies between one measurement
and another. To eliminate variability, two observers made two measurements of each 
patient.
Qualitative score of fibrosis distribution in AF and SR
To correlate the location of the LVA between the AF and SR maps, a qualitative 
score was defined based on 4 projections (antero-posterior [AP], postero-anterior 
[PA], superior [SUP] and inferior [INF]). In every view, LVA in SR and AF were 
compared, assigning different values according to the degree of similarity. In this way,
a value of 0 would correspond to discrepancies in the location of LVA between both 
maps; if LVA were in the same zones, the assigned value would be 2. For cases where 
there was no LVA in SR and therefore the comparison was not possible, the assigned 
value would be 1. Finally, values obtained for each projection were added, obtaining a
final value. If this value was equal to or greater than 5, it was defined as 
correspondence between LVA in both maps. Thus, patients in whom the location of 
the LVA differs in at least two projections are considered mismatched. This process 
was performed for both thresholds, 0.5 and 0.3 mV.
Follow-up
Antiarrhythmic medications were continued based on medical criteria. A blanking
period of 3 months after the ablation procedure was considered during which 
arrhythmia recurrence was not judged as ablation failure. All patients underwent 
ambulatory medical control visits 6 and 12 months after the ablation procedure. At 
each time point, a 12-lead electrocardiogram (ECG) and 24-hour Holter ECG were 
recorded. If patients presented symptoms earlier, they underwent additional 12-lead 
ECG and 24-hour Holter ECG. Arrhythmic recurrence at least one episode of 
sustained AF or atrial flutter (> 30 s) was considered and was recorded on a surface 
12-lead ECG or Holter ECG.
Statistical analysis
The IBM SPSS statistics package was used for statistical analysis. Numerical data
were tested for normality using the Shapiro-Wilk test. Numerical variables are 
expressed as the mean ± standard deviation. Categorical variables are expressed in 
percentages. Paired and unpaired t tests were used when appropriate. Categorical 
variables were compared between groups by using the χ2 test. The significance level 
was defined as p < 0.05. To evaluate interobserver concordance, the intraclass 
correlation coefficient was calculated.
Kaplan-Meier curves were created for the endpoint of arrhythmia-free survival. 
Arrhythmia-free survival was then compared between the groups using the log-rank 
test.
RESULTS
A total of 23 patients were included. Patient characteristics are shown in Table 1. 
All the studied variables had a normal distribution by the Shapiro-Wilk test.
Procedure
All patients were in AF before the procedure. Acute PVI was achieved in all 
patients. Two of them also had a history of common isthmus-dependent atrial flutter, 
so cavotricuspid isthmus ablation was also performed. Ablation lines were performed 
in 3 patients who presented atypical left atrial flutter during the procedure. 
The median procedure time (from femoral venous puncture to removal of all 
catheters) was 169.3 ± 29 min, and the median fluoroscopy time was 5.6 ± 2.5 min. 
The only complication derived from the procedure was one case of cardiac 
tamponade (4.3%), which was solved by pericardiocentesis.
Electroanatomic mapping and low voltage area study
Number and percentage of points. The mean number of points for maps in AF 
was 3428 ± 1159 points, whereas it was 2319 ± 1143 points for maps in SR.
Percentage of points with voltage lower than 0.5 mV and with voltage lower than 
0.3 mV was significantly higher in maps in AF compared to maps in SR: 38.2% of 
points < 0.5 mV in maps in AF vs. 22.9% of points < 0.5 mV in maps in SR (p < 
0.001); 22.3% of points < 0.3 mV in maps in AF vs. 14% of points < 0.3 mV in maps 
in SR (p < 0.001).
Mean voltage. The global mean voltage of maps in AF was significantly lower 
than the mean voltage of maps in SR: 0.62 ± 0.27 mV vs. 1.62 ± 0.7 mV (p < 0.001). 
When areas with voltages lower than 0.5 mV were selected, significant differences in 
mean voltage were not observed between the two types of maps (0.277 ± 0.02 mV vs. 
0.272 ± 0.01 mV, p = 0.27). No differences were found in the mean voltage in areas 
with voltages lower than 0.3 mV (0.192 ± 0.008 mV in maps in AF vs. 0.92 ± 0.007 
mV in maps in SR, p = 0.448).
Low voltage area measurement. For the 0.5 mV threshold, all patients had LVA 
when the maps were performed in AF, whereas only 52.2% of patients had LVA when 
the maps were performed in SR. For the 0.3 mV threshold, 78.2% of patients had LVA
in the AF maps, whereas only 43.5% of patients had LVA in the SR maps.
Although the global area of maps in AF was smaller than that of maps in SR 
(267.9 ± 44.5 cm2 vs. 285.7 ± 48.2 cm2, p < 0.001), areas with reduced voltages were 
significantly larger in maps in AF. Specifically, for the 0.5 mV threshold, the mean 
LVA in AF maps was 41.3 ± 42.5 cm2, whereas in maps in SR, it was 11.7 ± 17.9 cm2, 
p < 0.001. For the 0.3 mV threshold, the mean LVA in maps in AF was 15.6 ± 22.1 
cm2, whereas it was 6.2 ± 11.5 cm2 in maps in SR, p < 0.001 (Figs. 1, 2).
Qualitative score of assessment of fibrosis
For the 0.5 mV threshold, 91% of patients obtained a score equal to or greater 
than 5 points, which, considering the description of our score, means that LVA in SR 
was present as LVA in maps in AF. The remaining 9% did not have LVA in SR maps, 
so location comparison could not be made. For the 0.3 mV threshold, 52% of patients 
obtained a score equal to or greater than 5 points, which, considering our score, meant
that LVA in SR was present in AF. In 39% of patients, there was no LVA in maps in 
SR, so location comparison could not be made. Finally, in the remaining 9% of 
patients, the score was less than 4 points, so LVA in SR was not represented as LVA in 
AF (Figs. 3A, B; 4A, B).
Interobserver correlation. To assess interobserver correlation, the intraclass 
correlation coefficient was calculated based on the measurements carried out for each 
patient and each area by two independent observers. The results showed an adequate 
correlation with values greater than 0.8 in all cases: (i) Area measurement AF < 0.5 
mV: intraclass correlation coefficient 0.88, p < 0.001; (ii) Area measurement AF < 0.3
mV: intraclass correlation coefficient 0.92, p < 0.001; (iii) Area measurement SR < 
0.5 mV: intraclass correlation coefficient 0.89, p < 0.001; (iv) Area measurement SR 
< 0.3 mV: intraclass correlation coefficient 0.86, p < 0.001.
Follow-up
The mean follow-up time was 25 ± 12 months. Excluding the blanking period, 10
patients (43.5% of all patients) presented arrhythmic recurrence at the postablation 
follow-up. Among patients who had recurrence, 8 presented AF (80% of the patients 
with recurrence), whereas 2 presented atrial flutter (20% of the patients with 
recurrence).
The median arrhythmia-free survival at follow-up was 25.3 ± 3.7 months.
In the global sample, for the 0.5 mV threshold, the mean percentage of LVA in 
maps in SR was 4.2%, whereas it was 15.6% in maps in AF. For the 0.3 mV threshold,
the mean percentage of LVA in maps in SR was 2.2%, whereas it was 5.8% in maps in
AF. The relationship between the percentage of LVA and arrhythmic recurrences was 
studied. The statistical power of the study was too low to detect significant differences
in LVA according to the presence of recurrences, so the present results must be 
considered exploratory. For the 0.5 mV AF, patients with recurrences presented a 
greater percentage of LVA than patients without recurrences (19.1% vs. 9.8%, p = 
0.019). For the same threshold, the SR result was not significant (5.5% vs. 3.1%, p = 
0.381). For the 0.3 mV group, the percentage of fibrosis did not show a significant 
relationship with arrhythmic recurrences in either AF or SR (6.75% vs. 3.1%, p = 
0.738, 2.6% vs. 1.9%, p = 0.952).
According to receiver operating characteristic curves and to fibrosis stage I 
definition in previous articles [14], we studied the relationship of the percentage of 
LVA < 0.5 mV greater than 5% with arrhythmic recurrences. In AF, both variables 
showed an almost significant association (p = 0.06): 56.3% of patients that presented 
a percentage of LVA greater than 5% had arrhythmic recurrences whereas only 14.3% 
of patients with a percentage of LVA less than 5% had a recurrence. In SR, the result 
was not significant (p = 0.382) (Fig. 5).
DISCUSSION
Low voltage area studied by EAM of atrial bipolar endocardial signals has been 
recently established to define AF substrate invasively. As an advantage, it does not 
require additional approaches or catheters and does not pose an additional risk to 
patients who, because of clinical criteria, undergo this therapeutic approach. Most 
authors consider these LVAs as surrogates of fibrosis [15, 16]. In the present study, it 
was decided to use 0.3 and 0.5 mV as cutoffs for low voltage because there is a study 
[17] in which a cut-off point between 0.3 and 0.6 mV is proposed based on the 
histopathological study of acute and chronic ablation lesions performed in pig 
myocardium and because the most widely used voltage value in literature is 0.5 mV. 
Nevertheless, herein, there was no clear validation of a threshold that we have to 
consider fibrosis. Some authors have adopted a statistical approach, considering the 
5th percentile of all mapping points as a threshold for abnormal tissue. For example, 
Kapa and collaborators [18] proposed a threshold of < 0.2 mV for atrial fibrosis in the
posterior wall and in the area between the PV and LA and < 0.45 mV for the rest of 
the atrium based on mapping 20 patients with paroxysmal AF, 10 of whom had 
previous PVI. Another study [19] was carried out in patients with left accessory 
pathway ablation, some of whom had additional AF. In patients without AF, 95% of 
the electrogram voltage was greater than 0.38 mV, so they defined a fibrosis voltage 
threshold of 0.4 mV. Other studies have been carried out in patients with 
supraventricular tachycardia undergoing LA mapping: Saghy [20] established a cut-
off point between fibrotic and healthy tissue of 0.5 mV in a study of 9 patients, while 
Yagashita [21] proposed 1.17 mV in a study of 6 patients. In the literature, the most 
widely used voltage value is 0.5 mV, but it may not be a threshold sensitive enough to
identify areas with arrhythmogenic potential. Several studies [7–12] have assessed the
usefulness of individualized ablation guided by LVA, and most of them have used the 
0.5 mV threshold. In nearly all of them, LVA ablation has shown favourable results. 
However, these studies have important methodological differences, some of them in 
mapping that could influence LVA determination. These differences include mapping 
catheter electrode spacing, electrode size, tissue contact, signal filtering, map number 
of points and heart rhythm during mapping. In the present study, a multielectrode 
catheter with an electrode size of 1 mm2 was used, similar to that used in the studies 
of Yang [22] and Jadidi [10], while the rest of the studies used larger catheters. In 
healthy tissue, large catheters can cause a higher voltage record, whereas in areas with
some fibrosis, a voltage summation of healthy and fibrotic voltages can result in lower
amplitude signals [23]. Our mapping catheter, despite not having a direct contact 
force measurement, does have a tool that confirms proper contact before signal 
recording of a point. Adequate and consistent tissue contact is essential to avoid 
underestimation of endocardial signal voltage. Regarding the map number of points, 
the present work presents the advantage of high-density mapping. All maps presented 
more than 400 points, with a mean number of points in AF maps of 3428 and in SR 
maps of 2319 points, much higher than the average number of points from previous 
studies (100–200 points) with a maximum in Jadidi’s study [10] with 1024 points.
The main strength of the present work lies in its objective: comparison of LVA 
according to map rhythm. In none of the exposed studies, was mapping carried out in 
both rhythms in the same patient. The present results show that for a certain voltage 
threshold, LVA extension is greater in AF maps than in SR maps. Another finding in 
the same vein was that the percentage of points below both thresholds was higher in 
AF maps than in SR maps. Yagishita [24] obtained a similar result to the current one: 
the mean voltage in AF was lower than that in SR when mapping both rhythms in the 
same patient. Furthermore, they established that for the 0.5 mV threshold, the number 
of LVA in AF was greater than that in SR, which supports the present results; 
however, those findings do not provide information on the extent of LVA. Since 
fibrosis is defined histologically and cannot be modified depending on heart rhythm, 
these data support that acquisition mapping rhythm implies a variation in the voltage 
recorded at each endocardial point. In fact, as early as 2003, the Ndrepepal [25] group
assessed the mean voltage in the left and right atrium in SR and AF and observed that 
the voltage was significantly reduced when mapping was in AF. In addition, they 
observed that areas with the shortest AF length cycle had a greater voltage difference 
between AF and SR, suggesting a possible effect of rapid and disorganized 
depolarization on collected voltages. More recently, a Spanish study [26], carried out 
with a very accurate methodology, goes further and compares voltages of selected 
points in SR maps and in arrhythmia maps (in some cases AF and in others atrial 
flutter). The authors established that a value of 0.5 mV in SR maps corresponds to 
0.38 mV in atrial flutter maps and to 0.31 mV in AF maps. With these data and with 
those obtained in the current work, it was considered necessary to establish different 
voltage thresholds depending on the rhythm in which mapping is performed. 
Furthermore, these thresholds should be generalized to scientific studies that evaluate 
LVA ablation impact. Additionally, parameters and tools for mapping should be 
standardized so they can be properly compared and generalized to clinical practice in 
case of favourable results.
Since LVA was less extensive in SR maps, the SR LVA location to the AF LVA 
location was compared. The qualitative scale used did not allow comparison if there 
were no LVA areas in SR maps. It was observed that in most patients, LVA in SR was 
present in maps in AF. From our point of view, these data indicate that LVA in SR 
probably corresponds to fibrosis, but it does not allow us to determine if the 0.5 mV 
threshold supposes an overestimation of fibrosis zones in AF or an underestimation of
these areas in SR.
With respect to postablation clinical evolution, it must be emphasized that the 
present data are only descriptive and exploratory for further investigations. If LVA is 
considered as a marker of fibrosis and therefore as a possible factor influencing 
postablation outcomes, it was found, for the 0.5 mV threshold, a significant 
relationship between recurrences and absolute LVA percentage (p = 0.019). This 
relationship could not be detected in SR, of which results are not significant. Although
not clearly stated, it is possible that if the patient sample had been more numerous, 
extension of LVA in AF would have been a factor clearly related to arrhythmic 
recurrences in postablation follow-up. 
Limitations of the study
This study had few patients, although the sample number is similar to many 
previous publications that address atrial EAM. Areas in AF and SR were both 
measured manually, which may cause operator-dependent variations. However, 
intraclass correlation coefficients show adequate interoperator agreement. Because of 
this finding, this factor influence seems to play a minor role. The study was not 
designed and does not have a sufficient sample size to assess evolutionary data; thus, 
the results obtained are only exploratory.
CONCLUSIONS
Using the same voltage thresholds, LVA extension in AF is greater than in SR for 
patients with persistent AF. The location of LVA in SR is present in AF in most 
patients. These findings provide arguments for defining a different atrial fibrosis 
threshold based on EAM rhythm.
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Table 1. Clinical characteristics (n = 23).
Clinical characteristics
Age [years] 59.2 ± 7.6
Sex (male) 74% (n = 17)
AF time of evolution [years] 4.5 ± 3.8
Hypertension 62% (n = 12)
Diabetes mellitus 9% (n = 2)
Dyslipidemia 39% (n = 5)
Smoking 39% (n =9)
Sleep apnea syndrome 13% (n = 3)
Left atrium enlargement 87% (n = 20)
Heart disease 35% (n = 8)
Treatment
ACO 95.7% (n = 22)
AA 69.6% (n = 16)
BB 87% (n = 20)
CA 4.3% (n = 1)
Left atrium enlargement includes an anteroposterior diameter greater than 40 mm or 
an indexed volume greater than 35 mL/m2 by echocardiography or an indexed volume
greater than 53 mL/m2 by cardiac magnetic resonance; AF — atrial fibrillation; ACO 
— oral anticoagulant treatment; AA — antiarrhythmic treatment (it includes 
amiodarone, flecainide, propafenone and dronedarone); BB — beta-blockers 
treatment; CA — non-dihydropyridine calcium channel blockers treatment
Figure 1. Low voltage area (LVA) extension < 0.5 mV: comparison between maps in 
atrial fibrillation (AF) and maps in sinus rhythm (SR).
Figure 2. Low voltage area (LVA) extension < 0.3mV: comparison between maps in 
atrial fibrillation (AF) and maps in sinus rhythm (SR).
Figure 3. A. Comparison between atrial fibrillation (AF) and sinus rhythm (SR) maps
for the 0.3 mV threshold. Postero-anterior projection. Patient 1; B. Comparison 
between AF and SR maps for the 0.5 mV threshold. Postero-anterior projection. 
Patient 1. In both images, an appropiate match in low voltage area (LVA) location was
observed, although LVA extension was greater in the AF map. 
Figure 4. A. Comparison between atrial fibrillation (AF) and sinus rhythm (SR) maps
for the 0.3 mV threshold. Superior projection. Patient 2; B. Comparison between AF 
and SR maps for the 0.5 mV threshold. Superior projection. Patient 2. In both images, 
lack of low voltage area (LVA) in SR maps is observed, for 0.3 mV threshold as well 
as for the 0.5 mV threshold. In this case it is not possible to assess if LVA location 
matches appropriately.
Figure 5. A. Comparison between atrial fibrillation (AF) and sinus rhythm (SR) maps
for the 0.3 mV threshold. Anteroposterior projection. Patient 5; B. Comparison 
between atrial fibrillation (AF) and sinus rhythm (SR) maps for the 0.5 mV threshold. 
Anteroposterior projection. Patient 5. In both images, low voltage area (LVA) 
extension in AF is much greater than in SR.
Figure 6. A. Comparison between atrial fibrillation (AF) and sinus rhythm (SR) maps
for the 0.3 mV threshold. Superior projection. Patient 20; B. Comparison between AF 
and SR maps for the 0.5 mV threshold. Superior projection. Patient 20. In both 
images, an appropiate match in low voltage area (LVA) location is observed, although 
LVA extension is greater in the AF map.
Figure 7. A. Receiver operating characteristic curves; B. Low voltage area (LVA) 
Kaplan-Meier arrhythmia free survival, excluding blanking period. LVA indicates low 
voltage areas < 0.5mV in atrial fibrillation maps. 







